Akebia Therapeutics
245 First Street
Suite 1100
Cambridge
Massachusetts
02142
United States
Tel: 617-871-2098
Website: http://www.akebia.com/
385 articles about Akebia Therapeutics
-
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka
6/30/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka).
-
Akebia Therapeutics to Present at Jefferies Healthcare Conference
6/3/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2022
6/2/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 14,000 shares of Akebia's common stock on May 31, 2022, as inducements material to each such employee entering into employment with Akebia.
-
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
5/19/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.
-
Akebia Therapeutics’s partner Otsuka Pharmaceutical Co. announced plans to terminate its global license agreements with Akebia for vadadustat.
-
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
5/9/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced financial results for the first quarter ended March 31, 2022 and provided business updates.
-
Akebia Therapeutics to Report First Quarter Financial Results
5/2/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 following the close of financial markets.
-
In a regulatory filing, the Cambridge, Massachusetts-based company indicated that it plans to “refocus its strategic priorities” and lay off 42% of its workforce.
-
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022
4/6/2022
Akebia Therapeutics, Inc. today announced that it will present data at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022 (SCM22), which will take place on demand and live in Boston on April 6-10, 2022.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 04, 2022
4/4/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 53,000 shares of Akebia's common stock on March 31, 2022, as inducements material to each such employee entering into employment with Akebia.
-
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients
3/30/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Akebia's New Drug Application (NDA) for vadadustat.
-
The FDA has rejected Cambridge, Mass.-based Akebia Therapeutics’ New D2rug Application (NDA) for vadadustat, a therapeutic for anemia due to chronic kidney disease (CKD).
-
The FDA has a very busy week ending the month of March and moving into April, highlighted by a big AdCom vote on Amylyx's ALS candidate AMX0035 on March 30.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 02, 2022
3/2/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 12 newly-hired employees options to purchase an aggregate of 97,000 shares of Akebia's common stock on February 28, 2022, as inducements material to each such employee's entering into employment with Akebia.
-
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
3/1/2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2021.
-
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
2/22/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), and Vifor Pharma Group (Vifor Pharma), today announced that the companies have amended and restated the terms of their license agreement, pursuant to which Akebia Therapeutics, Inc. (Akebia) granted Vifor Pharma an exclusive license to sell vadadustat, Akebia's investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (CKD).
-
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights
2/9/2022
Akebia Therapeutics, Inc. today announced plans to release its financial results for the fourth quarter and full-year 2021 ended December 31, 2021 , on Tuesday, March 1 , 2022.
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022
2/1/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into employment with Akebia.
-
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference
1/10/2022
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.
-
Akebia Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET.